Know Your Ports - Oncology Nursing News
Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters …
T-DXd Improves PFS in HR+, HER2-Low/-Ultralow Metastatic …
Dec 11, 2024 · Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) demonstrated an improvement in progression-free survival (PFS), compared with treatment of physician’s …
How Nurses Help Patients With Prostate Cancer During Radiation …
Sep 23, 2024 · During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in Portland, Oregon, discussed some of radiation’s …
Adjuvant Olaparib Continues to Improve iDFS in BRCA1/2+, HER2
Dec 12, 2024 · The analysis occurred at a median follow-up of 6.1 years (max, 9.6 years) and 2.6 years since the previous analysis. The updated data for all first invasive disease-free survival …
How ctDNA Testing Is Being Used To Diagnose And Monitor Cancer
Dec 18, 2024 · “ctDNA testing looks for small pieces of DNA found in a patient’s blood that comes from cancer cells and tumors,” Grafton explains. “Screening for ctDNA can be used to detect …
Enhancing Early-Stage NSCLC Care: Streamlining Biomarker …
Nov 9, 2024 · Background. Early-stage non-small cell lung cancer (NSCLC) is a heterogeneous disease with diverse molecular profiles and treatment options. Recent advances in targeted …
Cosibelimab Approved by FDA for Metastatic, Locally Advanced …
Dec 13, 2024 · Cosibelimab-ipdl (Unloxcyt) has been granted FDA approval to treat adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not …
Oncology Drugs Approved by the FDA in August 2024 - Oncology …
Sep 3, 2024 · Throughout the month of August, several cancer therapies have been approved by the FDA for diseases including non-small cell lung cancer (NSCLC), cutaneous T-cell …
Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant …
Feb 17, 2023 · Tamoxifen, at a dose of 5 mg daily (babytam), continued to show a benefit over placebo in reducing the risk of recurrence from invasive breast cancers and ductal carcinoma …
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent ...
Apr 1, 2022 · PD-L1 combined positive score (CPS) may serve to predict whether a patient with PD-L1–expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) …